ZYDUS GROUP

History

YearDetail
1952 Cadila Laboratories Ltd. established by Mr. Ramanbhai B. Patel.
1995 - 1996 Acquired Indo Pharma Pharmaceutical Works Ltd – the group’s first acquisition.
1997 - 1998 Entered into JV with BYK Gulden, a German pharma major to set up a 50:50 JV.
1999 - 2000 Entered into JV with Sarabhai for consolidating its position in Animal Healthcare.
2000 - 2001 Zydus Research Centre set up at Moraiya and Acquired Recon Healthcare, which boosted Zydus’s strengths in southern markets.
2000 - 2002 Acquired German Remedies – the largest M&A in the Indian pharmaceutical sector at the time.
2001 - 2002 Acquired Aten and attained the top spot in the cardiovascular segment in India, Acquired USFDA approved API plant, Banyan Chemicals.
2002 - 2003 Zydus Pharmaceuticals (USA) Inc. incorporated.
2003 - 2004 Acquired Alpharma France (renamed Zydus France) – Zydus’s first international acquisition.
2005 - 2006 Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd.
2006 - 2007 Acquired Liva Healthcare and entered the dermatology market in India, Acquired Nippon Universal and entered the Japanese market.
2007 - 2008 Entered into branded generic market of Brazil with the acquisition of Quimica e Farmaceutica Nikkho do Brasil Ltda.
2008 - 2009 Acquired Laboratorios Combix in Spain, Simayla Pharma in South America, and Etna Biotech in Italy.
2009 - 2010 Launched first formulation using nano-technology platform in India – Oxalgin Nanogel.
2010 - 2011 Entered into a 50:50 JV with Bayer to set up a new marketing company. Entered into strategic agreement with Abbott for commercializing branded generics in emerging markets. Launched Vaxiflu – S, India’s first H1N1 vaccine.
2011 - 2012 Acquired 100% stake in Biochem, one of the top 40 pharma companies in India. Acquired Bremer Pharma GmbH to gain a global footprint in the animal healthcare business. Acquired the assets of US-based Nesher Pharmaceuticals Inc. Received USFDA approval of Baddi manufacturing plant.
2013 Received USFDA approval for initiating Phase I clinical trials of ZYDPLA1, a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes.
2014 Zydus launched world’s first biosimilar of adalimumab.
2016 Zydus acquired Zoetis, a global animal health company, Zydus and Takeda entered into partnership to address emerging infection diseases.
2017  Zydus Cadila acquired Sentynl Therapeutics Inc., US-based specialty company. Zydus launched India’s first Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4.
2018  Cadila Healthcare acquired 51% stake in Windlas Healthcare. Zydus partnered with Medicure to launch its NDA product, ZYPITAMAG.
2019 Zydus Wellness Ltd. completed the acquisition of Heinz India Private Limited.
2020 Cadila Healthcare Ltd. received USFDA approval to initiate clinical trials of desidustat in chemotherapy induced anemia (CIA).
2021 Zydus Cadila’s ZyCoV-D vaccine, the first plasmid DNA vaccine to be approved for human use in the world, was granted Emergency Use Authorization in India.
2022 Cadila Healthcare Limited rebranded to Zydus Lifesciences Limited. 
AI Sentiment